Vabicaserin - Pfizer
Alternative Names: PF-05208769; PF-5208769; SCA-136; Vabicaserin hydrochlorideLatest Information Update: 05 Nov 2023
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Antipsychotics
- Mechanism of Action Serotonin 2C receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bipolar disorders; Schizophrenia
Most Recent Events
- 10 May 2012 Discontinued - Phase-I for Schizophrenia in USA (PO)
- 27 Jan 2010 Phase-I clinical trials in Schizophrenia in USA (PO)
- 31 Dec 2009 Discontinued - Phase-II for Bipolar disorders in USA (PO)